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OBJECTIVE: In human somatic cells, telomeres shorten with successive cell divisions,
resulting in progressive genomic instability, altered gene expression, and cell death.
Recently, telomere-specific deoxyribonucleic acid-binding proteins, such as telomeric
repeat binding factor-1 (TRF1), have been proposed as candidates for the role of
molecules regulating telomerase activity, and they have been suggested to play key
roles in the maintenance of telomere function. The present study was designed to
assess TRF1 expression in human astroglial brain tumors and to speculate on the
clinical implications of its expression.
METHODS: Twenty flash-frozen surgical specimens obtained from adult patients who
underwent craniotomy for microsurgical tumor resection, histologically verified as
World Health Organization Grade II to IV astrocytomas, were used. Expression of
TRF1 in astrocytomas of different grades was studied by means of both immunohis-
tochemical and Western blotting analysis. The correlation between the extent of TRF1
expression and histological grading, performance status, and length of survival of
patients underwent statistical analyses.
RESULTS: TRF1 was expressed in all tumor samples. The level of its expression was
variable, decreasing from low-grade through high-grade astrocytomas (P  0.0032).
TRF1 expression correlated with the patient’s length of survival (P  0.001) and
performance status (P  0.001) and proved to be an independent indicator of length
of survival.
CONCLUSION: Our findings suggest that the loss of TRF1 expression capability, as a
result of down-regulation of TRF1 expression in malignant gliomas cells, may play a
role in the malignant progression of astroglial brain tumors.
KEY WORDS: Astroglial tumor, Brain tumor, Glioma, Telomere, Telomeric repeat binding factor
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Astroglial tumors represent the largesttumor entity in the central nervous sys-tem. Despite notable advances
achieved during recent decades in both surgi-
cal and chemotherapeutic/radiotherapeutic
approaches, an improved survival has not
been clearly documented. The World Health
Organization (WHO) guidelines for diffusely
infiltrating astrocytomas distinguish three
grades of malignancy (Grades II–IV) on the
basis of histopathological features that predict
patients’ survival (26, 27). The transition from
a low-grade astrocytoma (LGA) to a glioblas-
toma is associated with a stepwise accumula-
tion of genetic mutations. Although age, pre-
operative Karnofsky Performance Scale (KPS)
status, extent of resection, and histopatholog-
ical malignancy grade constitute widely rec-
ognized prognostic factors, additional indica-
tors are needed to more accurately determine
the patient’s prognosis and to identify novel
therapeutic approaches that can optimize the
patient’s outcome. Moreover, it is impossible
to predict the clinical outcome for the individ-
ual patient on the basis of histological grade
alone, because astrocytomas of the same tu-
mor grade may behave differently. In the stag-
ing of carcinogenesis, two phenomena have
been proposed. One is malignant transforma-
tion, which is the result of a multistep process
in which cells acquire mutations of genes that
activate proto-oncogenes or negate the action
of tumor suppressor genes. The other phe-
nomenon in carcinogenesis is immortalization
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(20). It has recently been speculated that changes in telomere
domain can result in genetic disorders and genomic variability
(33). Telomeres consist of long tandem arrays of TTAGGG
repeats bound by proteins, placed at the end of linear chro-
mosomes, which are involved in several essential biological
functions (4, 12). Telomeres protect chromosomes from recom-
bination, end-to-end fusion, and recognition as damaged de-
oxyribonucleic acid (DNA), providing a means for complete
replication of chromosomes. Furthermore, telomeres contrib-
ute to the functional organization of chromosomes within the
nucleus, participate in the regulation of gene expression, and
serve as a molecular clock that controls the replicative capacity
of human cells and their entry into senescence (4, 12). In
human somatic cells, telomeres shorten with successive cell
divisions, resulting in progressive genomic instability, altered
gene expression, and cell death (42) via p53-dependent or
-independent mechanisms (10, 51). This shortening in normal
human cells could monitor their replicative history (12, 21, 46).
In cancer cells, telomere length is dependent on the balance
between the loss of telomeric repeats during DNA replication
and the elongation of telomeric repeats mediated by telomer-
ase (54). In human tumors, telomere length is generally re-
duced. In human gliomas, hypervariability in length was ob-
served (29, 33, 37). These findings lead to the speculation that
changes in telomere domain contribute to the fundamental
molecular and structural alterations that create genomic insta-
bility in tumors (33). Telomerase is a ribonucleoprotein that
synthesizes telomeric repeats onto chromosome ends by use of
an endogenous ribonucleic acid as a template and provides
the molecular basis for unlimited proliferative potential (7, 8,
36). Two major subunits of the human telomerase core com-
plex have been identified, namely, hTERC and hTERT. The
first identified subunit, hTERC, serves as a template for telo-
mere elongation by telomerase, whereas the second subunit,
hTERT, contains a reverse transcriptase domain that catalyzes
this reaction (10). Recently, telomere-specific DNA-binding
proteins, such as TRF1, have been put forward as additional
candidates for the role of molecules modifying telomerase
activity, and they have been suggested to play key roles in the
maintenance of telomere function (1, 36, 48). TRF1 is a mam-
malian telomeric protein that binds to the duplex array of
TTAGGG repeats at chromosome ends. TRF1 has a number of
biochemical similarities to Rap1p, a distantly related DNA-
binding protein that functions at telomeres in yeast (5, 9). Like
Rap1p, TRF1 requires two Myb motifs for DNA binding.
Human TRF1 was found to form a homodimer through inter-
actions involving the N-terminal half of the protein. Like the
Rap1p protein, TRF1 may have an architectural role at telo-
meres. DNA bending by those telomeric proteins could induce
a higher-order structure at telomeres that is required for their
function. In particular, T-loop formation induced by TRF1
may act as a negative regulator of telomere lengthening oper-
ated by the telomerase (19). Thus, overexpression of TRF1
inhibits telomere elongation in telomerase-positive cells (45),
resulting in gradual and progressive telomere shortening to
the “mortality stages,” the proliferative barriers that lead to a
nondividing state and cell death (9, 45, 47). TRF1 accepts
adenosine diphosphate ribosylation catalyzed by the
tankyrase PARP. The adenosine diphosphate ribosylation of
TRF1 diminishes its ability to bind to telomeric DNA, allowing
telomerase to elongate telomeres and extending cellular life
span (13, 40, 44). The mutation or deletion of TRF1 can result
in telomere elongation and extend cell survival (47). Overex-
pression of a dominant negative TRF1, which removes endog-
enous TRF1 from telomeres, results in telomere lengthening in
telomerase-positive cells (24, 47). Therefore, the expression of
TRF1 is considered a physiological homeostatic mechanism
that controls the proliferative potential of normal cells by
inhibiting the activity of telomerase (45).
The main goal of the present study was to assess the extent
of TRF1 expression in human astroglial brain tumors of dif-
ferent histological grading. An attempt to correlate the level of




This study included tumor samples, histologically verified
as WHO Grade II to IV astrocytomas, obtained from adult
patients who had undergone craniotomy for microsurgical
brain tumor resection at the Neurosurgical Clinic of the Uni-
versity of Messina School of Medicine (Table 1). All tumors
were located in the supratentorial compartment.
Only patients who had undergone large, gross total resec-
tion of their neoplasms (95% of the tumor volume) were
eligible for the study. The patients affected by anaplastic as-
trocytoma (AA) and glioblastoma multiforme (GBM) were
treated, after surgical removal of the tumor, by fractionated
whole-brain irradiation (60 Gy). Patients with LGAs did not
undergo chemotherapy or radiotherapy after tumor resection.
Samples obtained from single or multiple stereotactic biopsies
were not included in the present study. We carefully excluded
tumors containing components that were suspect for oligo-
dendroglioma. No case of recurrent tumors and no patient
who underwent adjuvant therapy (radiotherapy and/or che-
motherapy) before surgery were used in the present study.
Tissue Samples
Twenty surgical specimens were evaluated. All tumor tis-
sue samples were obtained rapidly from resection specimens
within 15 minutes after surgical tissue removal. Three to seven
anatomically separate areas of tumor tissue were sampled
from each resection specimen, according to the volume of
resected tissue available. Specimens were taken from viable
areas of tumor, avoiding areas of gross necrosis. Tissue sam-
ples for the histological, immunohistochemical, and Western
blot analysis were taken from the same general region as the
tumor during surgery. Tissue was placed in cryovials and
immediately flash-frozen in liquid nitrogen in the operating
room and stored at 70°C. Both the adjacent tissue samples
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matched to the frozen tissue and additional tissue submitted
in toto from the resection specimens were used for histological
typing and grading. Normal brain tissue was used as control.
TRF1 Immunohistochemical Assessment
TRF1 assessment was performed on corresponding mirror-
image sections with a goat polyclonal antibody, anti-TRF1
(1:100; Santa Cruz Biotechnology, Inc., Santa Cruz, CA). As a
revealing system, secondary antibody biotin-streptavidin-
peroxidase (AEC kit; Universal Quick Kit; Vector Laborato-
ries, Burlingame, CA) was used. Briefly, surgical specimens
were mounted in embedding medium for frozen tissue spec-
imens and sectioned to 5-m thickness with a 2800 Frigocut
Cryostat (Reichert-Jung, Heidelberg, Germany). Sections were
mounted on glass slides and fixed in ice-cold acetone for 5
minutes. Each section was then rinsed three times in
phosphate-buffered saline, incubated for 5 minutes in 3% hy-
drogen peroxide (H2O2) to inhibit endogen peroxidase, and
then incubated overnight at 4°C with the primary antibody
against TRF1. After being rinsed three times in phosphate-
buffered saline, sections were incubated (15 min at room tem-
perature) with a secondary antibody (Vectastain Universal
Quick Kit; Vector), rinsed three times in phosphate-buffered
saline, then labeled (15 min at room temperature) with
streptavidin-peroxidase preformed complex (Universal Quick
Kit; Vector). Positive signal was stained brown-red with
3-amino-9-ethylcarbazole (AEC; Vector), counterstained with
hematoxylin, and mounted on aqueous mounting medium. As
negative control, the primary antibody was substituted with
nonimmune serum. Samples were then observed with a Zeiss
TABLE 1. Summary of demographic and clinical data of 20 patients with different grades of astrocytomaa
Patient
no.








1 39/M II L T 12 100 208b 690.7
2 42/M II R F 12 100 208b 673.5
3 31/F II L FT 1 100 208b 652.6
4 62/F III L FT 20 100 123 564
5 76/M III L O 12 80 62 522.6
6 70/M III R TO 16 60 48 375
7 29/M III L T 16 100 178 672.6
8 72/F III R T 8 100 158 722
9 72/M III R FT 24 100 158 537
10 74/M III R PO 12 80 53 543
11 68/F III L T 4 60 45 386
12 74/F III L PO 4 100 130 715
13 62/M IV L FPT 8 80 65 536
14 72/M IV R FPT 20 80 41 130
15 47/M IV L FT 12 100 27 280
16 79/F IV R T 8 90 37 433
17 61/M IV L O 4 80 60 522
18 73/M IV R FTP 4 80 32 128.5
19 50/M IV L TP 2 100 30 298
20 81/F IV L TP 12 90 88 452
a WHO, World Health Organization; L, left; R, right; F, frontal; P, parietal; T, temporal; O, occipital; KPS, Karnofsky Performance Scale; TRF1, telomeric repeat
binding factor-1; WB, western blotting.
b Still surviving at the end of follow-up (208 wk).
LA TORRE ET AL.
804 | VOLUME 56 | NUMBER 4 | APRIL 2005 www.neurosurgery-online.com
photomicroscope (Carl Zeiss Co., Oberkochen, Germany). The
percentage of cells exhibiting positive staining for TRF1 was
determined for each case. The area that seemed to have the
highest density of labeled cells was selected for counting. Only
clearly reactive nuclei were counted as positive. The number
of positive nuclei in a total of 100 cells was counted in five
high-power fields (200). The mean of the obtained value was
determined for each case. Sections were independently eval-
uated by two of the authors, who were blinded to the patient’s
identity. We intentionally decided not to use the intensity of
staining as a grading criterion, because an “intensity score” is
highly subjective and prone to variations among runs. A pre-




Frozen tumor tissues (50 mg) were harvested by homogeni-
zation with a Potter homogenizer in 15 volumes of ice-cold triple
detergent lysis buffer (20 mmol/L N-2-hydroxyethylpiperazine-
N'-2-ethanesulfonic acid, 9.2 mmol/L ethyleneglycol- O,O'-bis-
[2-amino-ethyl]- N,N,N',N'-tetra-acedic acid, 1 mmol/L ethyl-
enediamine tetra-acetic acid, 150 mmol/L NaCl, 0.1% sodium
dodecyl sulfate, 1% Igepal 40, 0.5% deoxycholic acid, pH 7.5;
protease inhibitors: 0.5 mmol/L phenylmethylsulfonyl fluoride,
apronin, pepstatin, and leupeptin [10 g/ml each]).
The concentration of total proteins in the samples was de-
termined by a Lowry method assay with albumin standards.
Approximately 50 g of total proteins was resolved in 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis,
and proteins were transferred laterally to nitrocellulose mem-
branes in a transfer buffer containing 0.192 mol/L glycine and
0.025 mol/L Tris (pH 8.3) with 10% methanol at a constant
voltage of 100 V for 1 hour at 4°C. Blots were blocked for 1
hour at room temperature in 5% nonfat milk in Tris-buffered
saline and 0.05% Tween-20.
Immunoblots were probed with goat polyclonal antibody
anti-TRF1 (Santa Cruz Biotechnology, Inc.), which recognizes
TRF1 at 76 kD. After incubation with primary antibody (1:200)
at room temperature for 2 hours, blots were incubated with a
rabbit anti-mouse immunoglobulin G secondary antibody (1:
1000; Dako, Carpinteria, CA) conjugated to peroxidase at
room temperature for 1 hour. Enhanced chemiluminescence
reagents were used to visualize immunolabeling on Kodak
Biomax ML chemiluminescent film (Amersham Biosciences,
Little Chalfont, Buckinghamshire, England). We used three
different exposures for each blot.
Quantification of TRF1 Level
Semiquantitative evaluation of protein levels detected by
immunoblotting was performed by computer-assisted densi-
tometric scanning (AlphaImager 4.2 Digital Imaging System,
Milan, Italy). Different times of exposure were used for each
blot (15–25 s), and longer exposures were performed in an
attempt to detect very low levels of TRF1 in normal brain
tissue. Data were acquired as integrated densitometric values
and expressed as percentages of the densitometric levels ob-
tained on scans from normal brain tissue used as control
visualized on the same blot in arbitrary densitometric units
(ADU). We used two different negative controls for each blot.
Statistical Data Analysis
Statistical data analysis was performed by use of one-way
analysis of variance with the Tukey post hoc correction for
multiple comparisons to compare the level of expression of
TRF1, as quantified by Western blot analysis, in LGAs, AAs,
and GBMs. The Spearman nonparametric correlation test was
used to assess the correlation between TRF1 expression and
the other included variables (WHO grading, survival, KPS
score, age). The 2 log-rank test was used to compare the
survival curves of patients with different expression of TRF1,
and results were displayed by use of a Kaplan-Meier curve.
Finally, to assess whether TRF1 was an independent indicator
of survival, a multivariate analysis was performed using the
logistic regression model. Survival was used as the indepen-
dent variable and TRF1 expression, age, and KPS score as
potential independent variables. Those variables were trans-
formed into binary variables to be used in the logistic regres-
sion model.
Computer software programs (INSTAT [version 3.0] and
PRISM [version 4.0], GRAPHPAD, San Diego, CA; and Med-
Calc [version 7.2.1.0], Mariakerke, Belgium) were used to per-
form the data analysis. A probability value of P  0.05 was
considered statistically significant. All values were expressed
as mean  standard deviation.
RESULTS
Twenty tumor samples were included in the study. The
tumor samples were resected from 13 men and 7 women,
whose ages ranged from 31 to 81 years; the mean age of these
patients at surgery was 61.3  16.1 years. KPS scores ranged
from 60 to 100% (mean, 89  13.4%). According to the revised
WHO classification (22, 23), tumors were diagnosed as LGA (3
patients), AA (9 patients), and GBM (8 patients).
Three patients with LGAs had an average age of 37.3  5.6
years; KPS score was 100% in all cases, and all patients’ length
of survival was longer than 208 weeks. Nine patients with
AAs had an average age of 66.3  14.6 years; the KPS score
was 86.7  17.3%, and the patients’ length of survival was
106.1  53.9 weeks. Eight patients with GBMs had an average
age of 65.6  12.7 years; the KPS score was 87.5  8.9%, and
the patients’ length of survival was 47.5  21.4 weeks. Total
length of follow-up was 208 weeks after surgery.
Immunohistochemical TRF1 Expression
TRF1 immunoreactivity was expressed at variable intensity
and distribution by tumor cells in 8 (40%) of 20 cases. In most
cells, the signal was generally weak and was observed in both
the nucleus and the cytoplasm. The percentage of tumor cells
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exhibiting positive staining for TRF1 was 3.2  1.4%. TRF1
expression varied from 6 to 10% in LGAs, from 0 to 8% in AAs,
and from 0 to 1% in GBMs (Fig. 1). TRF1 expression was
absent in normal brain tissue samples. Because of the low
percentage of immunostaining cells in TRF1-positive samples,
immunohistochemical results for TRF1 were not considered
for statistical analysis.
Western Blot Analysis for TRF1
A 76-kD TRF1 band was evidenced in all analyzed tumor
samples and was absent in normal brain tissue (Fig. 2A).
Densitometric analysis of bands revealed that such expression
varied among tumor samples, with a mean value of 500.6 
187.7 ADU. Mean TRF1 expression levels in LGAs were 672.4
 19.1 ADU; in AAs, those levels were 559.7  127.3 ADU;
and in GBMs, the TRF1 levels were 369.8  200.7 ADU (Fig.
2B), with a significant statistical difference (P  0.0032).
Correlation of TRF1 Expression with Grading, KPS
Score, and Length of Survival
The correlation between TRF1 expression levels, as mea-
sured by use of Western blot analysis, and histological grading
of tumor samples was assessed by use of the Spearman’s
nonparametric correlation test. A statistically significant in-
verse correlation was found (r2  0.47; P  0.001) (Fig. 3). The
same statistical test was used to measure the correlation be-
tween TRF1 expression levels and KPS score and age. A sta-
tistically significant correlation was recorded between TRF1
levels and KPS score, with an r2  0.21 and P  0.039 (Fig. 4).
No statistically significant correlation was found between
TRF1 expression and age.
The Kaplan-Meier analysis showed that patients with TRF1
expression of less than 500 ADU (mean value) had shorter
FIGURE 1. A, representative sec-
tion from immunohistochemical
analysis. TRF1 assessment was per-
formed on a tissue section obtained
from a histologically verified GBM
(Grade IV) using a goat polyclonal
antibody, anti-TRF1 (1:100). Only
clearly reactive nuclei were counted
as positive. TRF1 antibody stains a
single cancer cell (red-brown), whereas the other cells are negative (original
magnification, 63; scale bar  160 m). B, representative section from
immunohistochemical analysis performed on a tissue section obtained from a
histologically verified AA. TRF1 antibody stains a few cancer cells at low
intensity (red-brown). The vacuolar aspects are a result of freezing artifact
(original magnification, 250; scale bar  40 m). The number of positive
nuclei in a total of 100 cells was counted in five high-power fields. TRF1
expression was scored as 8% of positive cells. C, representative section from
immunohistochemical analysis performed on a tissue section obtained from a
histologically verified low-grade astrocytoma. TRF1 antibody stains both nuclei
and cytoplasm of a few cancer cells (red-brown) and stains microvasculature at
lower intensity (original magnification,250; scale bar 40m). The number
of positive nuclei in a total of 100 cells was counted in five high-power fields.
TRF1 expression was scored as 10% of positive cells.
FIGURE 2. A, representative Western blot. Immunoblots were probed
with goat polyclonal antibody anti-TRF1 at 76 kD. After incubation with
primary antibody (1:200) at room temperature for 2 hours, blots were
incubated with a rabbit anti-mouse immunoglobulin G secondary antibody
(1:1000) conjugated to peroxidase at room temperature for 1 hour. Vari-
able levels of TRF1 were detected in tumor specimens, with decreasing
expression levels from low-grade through high-grade astrocytomas. Time of
exposure was 15 minutes. Apparent double-banding in some of the tumor
samples was because of the intrinsic characteristic of the polyclonal anti-
body detecting full-length and C-terminally deleted TRF1 (TRF1 C).
NBT, normal brain tissue; LGA, low-grade astrocytoma. B, semiquantita-
tive densitometric analysis of the expression of TRF1 in different astroglial
brain tumors. Bar graph showing the different TRF1 expression levels (x
axis) according to the histopathological diagnosis (y axis) in three low-
grade astrocytomas (672.4  19.1), nine AAs (559.7  127.3), and eight
GBMs (369.8  200.7). Error bars indicate standard deviation. A one-
way analysis of variance with the Tukey post hoc correction for multiple
comparisons was used to compare the levels of expression of TRF1, as
quantified by Western blot analysis, in LGAs, AAs, and GBMs (P 
0.0032).
FIGURE 3. Graph showing correlation between TRF1 expression levels,
based on semiquantitative densitometric analysis, and the WHO tumor
grade. P  0.001; Spearman r2  0.47.
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survival times than those with values of greater than 500 ADU
(log-rank test P  0.001) (Fig. 5). To assess whether TRF1
expression was an independent prognostic factor, a linear
logistic regression analysis was performed. To perform the
analysis, length of survival was used as the dependent vari-
able and compared with three different independent variables:
age, KPS score, and TRF1 expression, age and KPS score being
well-known independent prognostic factors in human glio-
mas. TRF1 expression (using the binary value of500 or500
ADU) turned out to be an independent prognostic factor for
length of survival (P  0.032; odds ratio, 14.0).
DISCUSSION
The aim of our study was to assess the expression of TRF1
in diffusely infiltrating astrocytomas of different histological
grades. Using Western blot analysis, we found that TRF1 is
expressed at variable levels in astroglial brain tumors,
whereas its expression was not detectable in normal brain
tissue. Moreover, its expression seems to decrease from low-
grade through high-grade astrocytomas. As in almost all tu-
mors, malignant brain tumors are reported to be associated
with higher telomerase activity than benign tumors, such as
neuromas and meningiomas (41), or normal brain (50). Telom-
erase expression has also been associated with high prolifer-
ative index, grade of tumor, age, vascular endothelial prolif-
eration (28), and poor outcome (22, 32), and it increases with
malignancy from low-grade to high-grade astrocytomas (29).
In light of the recently identified role for telomerase in the
process of tumorigenesis, and in particular in the progression
of glioma malignancy, moving toward the study of molecular
mechanisms controlling telomerase activity was the next log-
ical research step and constituted the rationale of the present
investigation. Furthermore, it has been reported that telomer-
ase activity does not always correlate with the telomere length
found in cancer cells (35, 54). This means that the length of the
telomere may be regulated by factors other than telomerase
activity. In particular, in human brain tumors, it was recently
speculated that a number of gliomas are telomerase-negative,
suggesting that, in addition to the telomerase-dependent
mechanism, a telomerase-independent mechanism for telo-
mere length maintenance may be present in human gliomas
(35). These findings confirm that the regulation of telomerase
access to telomeres in human cells is not yet fully understood.
In the past few years, an increasing number of telomere-
associated proteins and their interacting partners have been
identified (15, 17, 39). Collectively, these telomeric proteins
may function to protect telomere integrity and functionality,
to connect the DNA damage repair network with the controls
of cellular senescence, to monitor telomere homeostasis, and
to modify the access of telomerase to telomeres. Recent studies
indicate that telomere-associated proteins can regulate telom-
erase accessibility in either positive or negative ways (16). The
first identified telomeric protein, TRF1, specifically binds to
duplex telomeric DNA and is involved in T-loop formation
(19), thus acting as a negative regulator of telomere length.
Overexpression of TRF1 inhibits telomere elongation in
telomerase-positive cells (45). TRF1 is involved in a negative
feedback mechanism that stabilizes telomere length (9, 11, 18,
43, 45, 47). Antisense experiments with human telomerase
ribonucleic acid indicate that telomerase inhibition may lead
to telomere shortening and cell death in human cell lines (35).
However, telomerase activity is absent in a number of human
tumors, such as in some astroglial brain tumors (35). This
means that a telomerase-independent mechanism for the reg-
ulation of telomere lengthening possibly exists in these
telomerase-negative tumors (35). Recent in vitro studies indi-
cate that not only hTERT but also TRF1 is an important reg-
ulator of telomerase activity in pancreatic cancer cells (52).
Overexpression of TRF1 in the tetracycline-responsive human
fibrosarcoma cell line HTCC75 resulted in a gradual decline in
telomere length (38), and it has been reported that the forced
tethering of a large number of TRF1 molecules to a single
telomere induces a significant shortening of telomere length
(1). Yokota et al. (54) suggest that TRF1 is up-regulated in
hepatocellular carcinoma with elongated telomeres. These
findings confirm the hypothesis that in human cancer cells, an
overexpression of TRF1 may result in a progressive telomere
shortening. An important question is how TRF1, which binds
along the length of the telomere, modulates telomerase, an
enzyme that acts at telomere termini. One mechanism that
could be considered in this context is that accessibility of a
DNA end to telomerase is diminished by the presence of TRF1
FIGURE 5. Kaplan-Meier survival curves for groups of diffusely infiltrat-
ing astrocytomas classified according to their TRF1 expression. Follow-up
was ended at 208 weeks after surgery. Survival was significantly longer in
patients affected by astrocytic tumors with TRF1 expression levels 500
ADU than in those with a lower expression log-rank P  0.001.
FIGURE 4. Graph showing correlation between TRF1 expression levels,
based on semiquantitative densitometric analysis, and the KPS score. P 
0.0039; Spearman r2  0.21.
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on or near the telomere terminus. An alternative proposal has
recently emerged from the finding that telomeres fold back,
forming a large duplex lariat called the T loop (19). In the T
loop, the 3' single-stranded telomeric overhang of TTAGGG
repeats is tucked into the duplex part of the telomeric repeat
tract. The T loop is proposed to sequester telomeres from
activities that might act on chromosome ends, including te-
lomerase. In vitro studies suggest that telomerase requires an
accessible 3' overhang (30, 31, 49), a structure predicted to be
absent from T loops. Therefore, T loops could control the
action of telomerase at individual chromosome ends. On the
basis of biochemical studies, the formation of T loops was
proposed to involve both TRF1 and TRF2. TRF1 induced
bending, looping, and pairing of duplex telomeric DNA (5, 6,
18, 19), facilitating the folding back of the telomere.
As far as we know, no other studies regarding TRF1 expres-
sion in brain tumors are available in the current literature. To
address this issue, we recently analyzed TRF1 expression in a
pilot panel of human brain tumors, including benign neo-
plasms such as meningiomas and malignant histotypes such
as AA (3, 14). Typically, TRF1 was expressed to various ex-
tents in meningiomas and was far less detectable in AA (WHO
Grade III) (3). This previous observation suggested that TRF1
expression was inversely correlated to proliferation and ma-
lignancy. In the present investigation, we analyzed TRF1 ex-
pression in 20 human brain glioma specimens, including
LGAs (WHO Grade II), AAs (WHO Grade III), and GBMs
(WHO Grade IV). TRF1 was detected in all tumor samples,
whereas it was not detected in normal brain tissue. Moreover,
its expression seemed to be inversely correlated with histolog-
ical grading. Of note, it is somewhat paradoxical that TRF1
levels are undetectable in normal brain tissue but that lower
levels correlate with higher tumor grade. However, our ob-
servation of an absence of a constitutive expression of TRF1 in
the nonneoplastic brain tissue is consistent with similar obser-
vations in gastrointestinal, lung, and adrenal tissues (2, 23, 36).
Furthermore, a tissue-specific behavior can be suggested
because of the contrasting observations reported in the current
literature regarding the role of TRFs. Actually, a down-
regulation of TRF1 gene expression may be important to main-
tain telomere length in gastric cancer (53), whereas up-
regulation of specific telomere-binding proteins, such as TRF2,
may contribute to telomere maintenance in malignant lym-
phoma (25).
Our observations are consistent with those of Matsutani et
al. (34) on gastric cancer. In that study, TRF expression levels
were higher in cancer cells compared with nonneoplastic mu-
cosa. Furthermore, the authors assessed that there are cancer
cells with long telomeres, high telomerase activity, and higher
TRF expression, and there are cancer cells with short telo-
meres, low telomerase activity, and lower TRF1 expression
levels. Ohyashiki et al. (38) reported that TRF1 expression was
significantly elevated in patients with acute lymphoblastic
leukemia compared with those in acute myeloid leukemia and
that TRF1 expression tended to be higher in patients without
telomere shortening and in those with hTERT expression.
Together, these observations suggest that TRF1 may act to
monitor telomere length under the condition of up-regulated
telomerase activity in some neoplastic cells.
According to the model of Smogorzewska et al. (45), telo-
meres can exist in two states: an “open” state, which allows
telomerase to elongate the telomere, and a “closed” state, in
which the enzyme cannot access or extend the telomere ter-
minus. The switching between these two states is proposed to
be governed by the telomere binding proteins TRF1 and TRF2
in human cells, which act as negative regulators through
promoting the closed state. It can be suggested that in some
nonneoplastic cells, short telomeres would not bind sufficient
amounts of TRF1 or TRF2. In cancer cells, as telomeres are
elongated by telomerase, they will bind a greater number of
the negative regulators, increasing the chance of a switch to
the closed state. This is therefore consistent with our observa-
tions that glioma cells express higher levels of TRF1 compared
with normal brain tissue and with our previous observations
that TRF1 is expressed at a high level in meningiomas as well
(3, 14).
After switching to the closed state, namely the T-loop state,
telomerase would no longer be able to elongate the telomere
terminus. The telomere will gradually lose sequences with
each cell division, leading to a smaller number of bound
negative regulators and an improved chance of switching back
to the open state. As a result, each individual telomere will
approach a steady-state length determined by the activity of
telomerase, the expression level of TRF1 and TRF2, and other
regulatory factors (e.g., tankyrase). Eventually, this sequence
loss would result in diminished binding of TRF1 and TRF2 to
the telomere, which would consequently form T loops at a
lower rate (or at a reduced frequency). The resulting (tempo-
rary) persistence of an unfolded telomere, a substrate for
telomerase, would then again lead to telomere elongation (45).
TRF proteins are therefore necessary to limit telomere elon-
gation. In the early stages of carcinogenesis of human gliomas,
this mechanism of control can be induced by the telomere
elongation by telomerase; in later stages, this control mecha-
nism can be lost.
To completely ascertain the truth of this hypothesis, the
mutational status of cells, the correlation with genomic insta-
bility, and telomere length as well as telomerase activity
should be analyzed in these cells. The lack of these data
represents a strong limit of the study. Nevertheless, this article
represents a preliminary study to assess whether TRF1 may
play a role in the multifactorial oncogenesis of human glio-
mas. Further studies are warranted to draw definitive
conclusions.
CONCLUSION
TRF1 was expressed in astroglial brain tumors of different
grades, whereas it was not expressed in normal brain tissue.
Such expression decreased from low-grade through high-
grade astrocytomas. This finding may suggest that the loss of
TRF1 expression capability, being the result of down-
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regulation of TRF1 expression in malignant gliomas cells, may
play a role in the cell immortalization of astroglial brain tu-
mors. Confirmation of a role for TRF1 in the carcinogenesis of
diffusely infiltrating astrocytomas would require a large-scale
study using molecular techniques, showing that this parame-
ter does indeed influence the tumor sequence. The next step
for the near future may be to determine how to incorporate
such biological information into the treatment of diffusely
infiltrating astrocytomas.
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This is a relatively simple study that demonstrates a corre-lation between telemeric repeat binding factor 1 (TRF1)
and tumor grade for gliomas. Although association does not
prove causation, these findings support a general theme that
loss of control over the ability of the genome to replicate with
efficiency and stability is a characteristic of malignant gliomas.
Many reports demonstrate significant genomic mutations in
gliomas and that these mutations increase both over time and
as tumors evolve into a higher grade. Most of the mutations
are ignored or are considered not important (i.e., random).
However, randomness of genomic mutations may be the re-
sult of loss of control over a stable mitotic process, and alter-
ations in telomeres can provide one way in which this can
occur. Altered telomeres may preclude accurate alignment of
chromosomes in metaphase, and this can produce further
mutations and the genomic chaos found in glioblastoma.
Joseph M. Piepmeier
New Haven, Connecticut
Telemeres are tandem arrays of TTAGGG repeats placed atthe end of linear chromosomes, which are involved in
several essential biological functions. Telomeres shorten with
successive cell divisions, resulting in progressive genomic in-
stability. Telomere-specific deoxyribonucleic acid binding
proteins, such as TRF1, have been suggested to be important
in the maintenance of telemere function. In this study, expres-
sion of TRF1 was examined in a number of astrocytoma tumor
specimens. The results of this relatively small study of 20
surgical specimens demonstrate that there is a decrease in the
expression of TRF1 in the higher-grade tumors in comparison
to low-grade tumors. Some of the results may be explained by
age, in that those patients with low-grade tumors in this study
tended to be younger and therefore had higher TRF1 expres-
sion. One would like to see a study with normal brain tissue
either in regions surrounding the tumor or in patients under-
going surgery for other reasons to determine whether there
really is a difference in the expression of TRF1 in tumor tissue
in comparison to normal age-matched brain tissue. Neverthe-
less, there is some suggestion in these data that loss of TRF1
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